Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind …
A Deodhar, PS Helliwell, WH Boehncke, AP Kollmeier… - The Lancet, 2020 - thelancet.com
Background Many patients with psoriatic arthritis have an inadequate response to tumor
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via …
necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via …
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
PJ Mease, P Rahman, AB Gottlieb, AP Kollmeier… - The Lancet, 2020 - thelancet.com
Summary Background The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in
psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL …
psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL …
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome …
DJ DeAngelo, RM Stone, ML Heaney, SD Nimer… - Blood, 2006 - ashpublications.org
Abstract Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III
receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor …
receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor …
Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia
Therapeutic options are limited and the prognosis is poor for patients with fludarabine‐
refractory B‐cell chronic lymphocytic leukemia (CLL). Bortezomib induces apoptosis in vitro …
refractory B‐cell chronic lymphocytic leukemia (CLL). Bortezomib induces apoptosis in vitro …
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double …
BG Feagan, BE Sands, WJ Sandborn… - The Lancet …, 2023 - thelancet.com
Background Despite the introduction of new monoclonal antibodies and oral therapies for
the treatment of ulcerative colitis, clinical remission rates remain low, underscoring the need …
the treatment of ulcerative colitis, clinical remission rates remain low, underscoring the need …
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active …
JS Smolen, ME Weinblatt, S Sheng… - Annals of the rheumatic …, 2014 - ard.bmj.com
Objectives The safety and efficacy of sirukumab, an anti-interleukin-6 (IL-6) monoclonal
antibody, were evaluated in a 2-part, placebo-controlled phase II study of patients with active …
antibody, were evaluated in a 2-part, placebo-controlled phase II study of patients with active …
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non–small-cell lung cancer
MP Fanucchi, FV Fossella, R Belt, R Natale… - Journal of Clinical …, 2006 - ascopubs.org
Purpose To evaluate the efficacy and toxicity of bortezomib±docetaxel as second-line
therapy in patients with relapsed or refractory advanced non–small-cell lung cancer …
therapy in patients with relapsed or refractory advanced non–small-cell lung cancer …
Long‐term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin‐23, through two years: Results from a phase III …
IB McInnes, P Rahman, AB Gottlieb… - Arthritis & …, 2022 - Wiley Online Library
Objective To assess long‐term efficacy and safety of guselkumab, an interleukin‐23 p19
subunit (IL‐23p19) inhibitor, in patients with active psoriatic arthritis (PsA) from the phase III …
subunit (IL‐23p19) inhibitor, in patients with active psoriatic arthritis (PsA) from the phase III …
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER …
PJ Mease, PS Helliwell, DD Gladman… - The Lancet …, 2021 - thelancet.com
Background Guselkumab was efficacious in reducing signs and symptoms of psoriatic
arthritis in the phase 3 DISCOVER-1 and DISCOVER-2 studies. We aimed to evaluate the …
arthritis in the phase 3 DISCOVER-1 and DISCOVER-2 studies. We aimed to evaluate the …
Efficacy and safety of guselkumab, an interleukin‐23p19–specific monoclonal antibody, through one year in biologic‐naive patients with psoriatic arthritis
IB McInnes, P Rahman, AB Gottlieb… - Arthritis & …, 2021 - Wiley Online Library
Objective Guselkumab, a human monoclonal antibody specific to interleukin‐23p19,
demonstrated efficacy and safety versus placebo through week 24 of the phase III …
demonstrated efficacy and safety versus placebo through week 24 of the phase III …